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Abstract Mass spectrometry (MS) imaging links molecular
information and the spatial distribution of analytes within a
sample. In contrast to most histochemical techniques, mass
spectrometry imaging can differentiate molecular modifica-
tions and does not require labeling of targeted compounds.
We have recently introduced the first mass spectrometry
imaging method that provides highly specific molecular
information (high resolution and accuracy in mass) at cellular
dimensions (high resolution in space). This method is based
on a matrix-assisted laser desorption/ionization (MALDI)
imaging source working at atmospheric pressure which is
coupled to an orbital trapping mass spectrometer. Here, we
present a number of application examples and demonstrate
the benefit of ‘mass spectrometry imaging with high resolu-
tion in mass and space.’ Phospholipids, peptides and drug
compounds were imaged in a number of tissue samples at a
spatial resolution of 5–10 lm. Proteins were analyzed after
on-tissue tryptic digestion at 50-lm resolution. Additional
applications include the analysis of single cells and of human
lung carcinoma tissue as well as the first MALDI imaging
measurement of tissue at 3 lm pixel size. MS image analysis
for all these experiments showed excellent correlation with
histological staining evaluation. The high mass resolution
(R = 30,000) and mass accuracy (typically 1 ppm) proved to
be essential for specific image generation and reliable
identification of analytes in tissue samples. The ability to
combine the required high-quality mass analysis with spatial
resolution in the range of single cells is a unique feature of
our method. With that, it has the potential to supplement
classical histochemical protocols and to provide new insights
about molecular processes on the cellular level.
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H&E Hematoxylin and eosin staining
LC Liquid chromatography
MALDI Matrix-assisted laser desorption/ionization
MS Mass spectrometry
MS/MS Tandem mass spectrometry
PC Phosphatidylcholine
Ppm Parts per million
RMS Root mean square
SIMS Secondary ion mass spectrometry
SM Sphingomyelin
TOF Time-of-flight (mass spectrometer)
Introduction: Mass spectrometry imaging
Mass spectrometry (MS) is a universal and prominent tool
in analytical chemistry. This method can provide qualita-
tive as well as quantitative information for a wide variety
of compound classes. The molecular mass of a compound,
calculated from the m/z value of the corresponding ion, can
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be used for (tentative) identification. Ion fragmentation
experiments (often called ‘tandem MS’ or ‘MS/MS’
experiments) provide information about the molecular
structure of an analyte. Peak intensities in mass spectra can
be calibrated for analyte quantitation. Mass spectrometry
imaging combines these capabilities with information on
the location of analytes within a sample. The spatial dis-
tribution can provide valuable additional information about
the function and properties of an analyte, which would be
lost in typical MS measurements of bulk (homogenized)
samples. The first spatially resolved measurements in mass
spectrometry were obtained with laser desorption ioniza-
tion (LDI) in the 1970s (Hillenkamp et al. 1975a, b), but
were limited to the analysis of smaller ions, predominantly
of inorganic compounds. The investigation of larger
(bio)molecules by mass spectrometry was made possible
by the introduction of ‘soft ionization methods,’ namely
electrospray (ESI) (Fenn et al. 1989) and matrix-assisted
laser desorption/ionization (MALDI) (Karas et al. 1985;
Karas and Hillenkamp 1988) in the 1980s. The first
imaging application of MALDI was described in 1994
(Spengler et al. 1994). These experiments demonstrated
that larger organic molecules such as peptides, which are
thermally labile and which require matrix assistance, can
be detected in a spatially resolved manner using a highly
focused pulsed ultraviolet (UV) laser beam. This concept
was taken up and extended to the analysis of tissue in the
following years (Caprioli et al. 1997; Stoeckli et al. 2001).
Today mass spectrometry imaging is one of the most active
fields in mass spectrometry. While MALDI and secondary
ion mass spectrometry (SIMS) (Boxer et al. 2009) are the
most widely used ionization techniques for mass spec-
trometry imaging, a number of alternative techniques have
been developed in recent years. In particular, atmospheric
pressure ionization techniques such as desorption electro-
spray (DESI) (Eberlin et al. 2010), low-temperature plasma
(LTP) (Liu et al. 2010) and laserspray ionization (Richards
et al. 2011) are increasingly operated in imaging mode.
MALDI can also be operated at atmospheric pressure
(Laiko et al. 2000), but it has mostly been employed in high
vacuum ion sources.
A schematic representation of a MALDI mass spec-
trometry imaging experiment is shown in Fig. 1. The
sample (tissue section) is covered with matrix in order to
allow desorption and ionization of bioorganic analytes. A
laser beam illuminates a defined area of the sample and
desorbs and ionizes material from the surface (Fig. 1a).
The resulting ions are transferred to the mass spectrometer,
and a mass spectrum is acquired (Fig. 1b). Subsequently,
the sample is moved by a defined distance, and the next
position on the sample is analyzed the same way. Several
thousand spectra are typically acquired sequentially in this
manner. MS images of a selected analyte peak are
generated after the measurement by extracting the signal
intensity within a certain m/z window. The intensities are
plotted as gray scale values for each pixel in a grid rep-
resenting the corresponding positions on the sample
(Fig. 1c). These ‘MS images’ or ‘selected ion images’1
represent the spatial intensity distribution of a certain
m/z signal, which can be assigned to a certain compound.
Separate MS images can be generated for each signal in the
mass spectrum. Therefore, mass spectrometry imaging is
an ‘untargeted’ and multiplexed method. All desorbed and
ionized compounds in the sample are detected, regardless
of being known or unknown, expected or unexpected. This
is a major advantage compared to other imaging techniques
such as histochemical staining which requires the avail-
ability of a suitable antibody.
A number of compound classes have been analyzed by
MALDI imaging including peptides (Chen et al. 2010;
Stoeckli et al. 2002), proteins (Chaurand et al. 1999;
Reyzer and Caprioli 2007), lipids (Jackson et al. 2005;
Trim et al. 2008) and drug compounds (Stoeckli et al.
2007a). More details about MS imaging of these compound
classes are covered in the respective sections below.
Today mass spectrometry imaging is used in a broad
range of applications. The vast majority of studies are
focusing on tissue originating from animal models or on
human clinical tissue originating from surgical interven-
tions. The targeted diseases include Parkinson’s (Stauber
et al. 2008) and Alzheimer’s disease (Rohner et al. 2005) as
well as Duchenne muscular dystrophy (Benabdellah et al.
2009b). Numerous studies of clinical tissue focused on
cancer, for example prostate cancer (Cazares et al. 2009),
breast cancer (Balluff et al. 2010), gastric cancer (Balluff
et al. 2011a), adenocarcinoma (Djidja et al. 2009) and
ovarian cancer (El Ayed et al. 2010). Additional topics in
MS imaging studies included the analysis of plants (Lee
et al. 2012; Kaspar et al. 2011; Peukert et al. 2011), insects
(Vanickova et al. 2012) and microorganisms (Esquenazi
et al. 2008; Yang et al. 2009).
A number of review articles about mass spectrometry
imaging have been published in recent years. An extensive
overview that covers instrumental topics as well as appli-
cation areas is found in McDonnell and Heeren (2007). The
main ionization techniques, namely MALDI, SIMS and
DESI, are compared in Po´l et al. (2010). The perspectives
of MS imaging for clinical research focusing on protein
analysis are covered in Rauser et al. (2010a) and Balluff
et al. (2011b). A review by Schwamborn is specifically
targeted at biomarker discovery approaches by MALDI
1 The term ‘MS image’ will be used in this work to describe the
outcome of an MS imaging experiment in a general meaning.
‘Selected ion image’ will be used when referring to the spatial
intensity distribution of a specific ion.
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imaging (Schwamborn 2012). Multi-modal approaches and
details on matrix application methods are included in
Chughtai and Heeren (2010). Watrous et al. (2011) cover
current applications and future perspectives of MS imaging
in biological research.
In this review, we discuss MALDI-based mass spec-
trometry imaging with a focus on spatial resolution and
molecular information content. We describe the method-
ology and application of a recently developed mass spec-
trometry imaging method with high resolution in mass
(R = 30,000) and space (pixel size 3–10 lm).
Critical parameters in mass spectrometry imaging
Mass spectrometry imaging is a highly complex and
interdisciplinary analytical technique. This section covers
selected fundamental and practical aspects that have a
significant effect on the outcome of an MS imaging
experiment.
Sample preparation
Sample preparation is probably the most critical step in
mass spectrometry imaging. All procedures should be
optimized as to retain the native spatial distribution and
molecular identity of analyte compounds in the sample as
far as possible. Mass spectrometry imaging experiments
are typically performed on (thin) tissue sections. However,
classical embedding material for sectioning such as ‘opti-
mal cutting temperature’ compound (OCT) should be
avoided if possible. These polymers often result in sub-
stantial ion suppression and background signals which can
severely interfere with mass spectrometric analysis.
Therefore, cryosections of tissue without embedding are
used if possible. More delicate samples can be prepared
with embedding materials that have been reported to be
compatible with mass spectrometry imaging, this includes
carboxymethyl cellulose (CMC) (Kawamoto 2003), gela-
tine (Altelaar et al. 2005), a polymer compound (Strohalm
et al. 2011) and tragacanth gum (Brignole-Baudouin et al.
2012).
The second crucial step in sample preparation is the
application of matrix which is necessary to desorb and
ionize sample components. The matrix needs to interact
with the sample (surface) in order to extract analytes from
the tissue and incorporate them into matrix crystals. At the
same time, spatial integrity of the sample has to be pre-
served and analyte migration should be limited as far as
possible. A number of sample preparation methods have
been developed for MALDI imaging. A simple way of
matrix application is spraying of a concentrated matrix
solution by means of a thin-layer chromatography (TLC)
sprayer (Stoeckli et al. 2007b). This method provides
Fig. 1 Scheme of the mass spectrometry imaging process. a The tissue section is covered with matrix and irradiated by a pulsed laser beam.
b Mass spectrum acquired from the tissue section. c MS images of different m/z peaks
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effective analyte incorporation, but can also lead to sub-
stantial spatial spreading of analytes if spraying conditions
are not carefully controlled. An increasing number of
commercial matrix application devices have been devel-
oped recently. They include the ‘ImagePrep’ (Bruker
Daltonik, Bremen, Germany), which utilizes ‘vibrational
vaporization’ to generate a spray of matrix droplets
(Schuerenberg et al. 2007), and the ‘SunCollect’ sprayer
(SunChrom, Friedrichsdorf, Germany), which employs a
pneumatic sprayer. Both systems can achieve matrix
crystal sizes below 50 lm in diameter. Spotting devices for
MALDI matrix include the ‘CHIP-1000’ (Shimadzu Corp.,
Kyoto, Japan), which is based on piezoelectric technology,
and a spotter from Labcyte (Sunnyvale, CA, USA), which
is based on acoustic droplet deposition (Aerni et al. 2006).
These systems provide matrix deposition spots of about
200 lm in diameter. High spatial resolution in MALDI
imaging requires matrix crystals which are in the range of
the laser spot size, that is the intended pixel size. Therefore,
a two-step approach including matrix sublimation and
subsequent recrystallization was developed by Bouschen
et al. (2010). This method provides homogeneous matrix
coverage and allows MALDI imaging at 1–2 lm spatial
resolution. Similar approaches were developed by Thomas
et al. (2012) and Yang and Caprioli (2011), which were
applied to lipids and proteins, respectively. A pneumatic
spraying device capable of obtaining matrix crystals below
10 lm was developed by Bouschen et al. (2010).
Irrespective of the matrix application method, a certain
level of experience and practice is needed in order to obtain
suitable results. Great care should be taken during each
step of sample preparation, and experimental parameters
should be adapted for each application (sample type and
targeted compounds). This includes the choice of matrix
which has a significant effect on crystal size and the set of
compound classes that can be detected. The first MALDI
imaging experiments were performed with 2,5-dihydroxy-
benzoic acid (DHB), and this matrix is still used in many
studies, mainly for lipids and small molecules (Debois
et al. 2010; Groseclose et al. 2007; Spengler and Hubert
2002; Spengler et al. 1994). a-Cyano-4-hydroxycinnamic
acid (CHCA or HCCA) is also mainly used for small
molecules, especially for peptides (Schwartz et al. 2003)
and drug compounds (Prideaux et al. 2011; Stoeckli et al.
2007a). Proteins are typically analyzed with sinapinic acid
(SA, 3,5-dimethoxy-4-hydroxycinnamic acid) (Grey et al.
2009; Leinweber et al. 2009; Yang and Caprioli 2011).
While most MALDI imaging experiments were performed
in positive ion mode, an increasing number of studies in
negative ion mode has been reported, often using 9-ami-
noacridine (9AA) as matrix (Shroff et al. 2008; Benab-
dellah et al. 2009a; Burrell et al. 2007). Matrix compounds
that can be used in positive as well as in negative mode
include 4-nitroaniline and 1,5-diaminonapthalene (Thomas
et al. 2012).
Mass spectral data
An important factor in generating MS images is the ‘bin
width,’2 which defines the integration range on the
m/z scale for a certain imaged ion signal. Intensity values
for pixels in the MS image are calculated by integrating a
small m/z window within the corresponding mass spec-
trum. Intensity values of two peaks are added up if they fall
in the same bin. Thus, the bin width has significant influ-
ence on the generated MS image and has to be chosen
according to the complexity of the sample and the resolu-
tion and accuracy of the mass spectral measurement
(examples are shown in Figs. 6, 8). Consequently, the
choice of the mass analyzer has significant impact on the
quality of MS images.
The most widely used detectors for MALDI imaging are
time-of-flight (TOF) mass spectrometers. These instru-
ments are sensitive and are available in many (bio)ana-
lytical laboratories. They have been employed for a wide
range of applications, such as MS imaging of lipids
(Benabdellah et al. 2009b; Thomas et al. 2012; Chen et al.
2009), drugs/metabolites (Benabdellah et al. 2009a;
Stoeckli et al. 2007a) and peptides/proteins (Stoeckli et al.
2002; Mange et al. 2009; Lemaire et al. 2006, 2007b;
Francese et al. 2009; El Ayed et al. 2010; Rohner et al.
2005). Time-of-flight mass spectrometers in reflection
mode reach a mass resolving power of up to R = 30,000
and mass accuracies better than 5 ppm. However, this
performance is only obtained for measurements of
homogenized thin-layer samples. In MS imaging experi-
ments, the three-dimensional structure of the sample affects
ion flight times and results in significantly lower mass
resolution and mass accuracy. Height differences, which
cannot be entirely eliminated, lead to inhomogeneity in the
acceleration field and thus to a shift in detected flight time
(and the corresponding m/z value). Mass accuracy of axial
TOF mass spectrometers under tissue imaging conditions is
in the range of several tens of ppm if the measurement is
controlled carefully. However, mass deviations up to
m/z 0.5 are also not uncommon in MS imaging experi-
ments. One way to reduce these detrimental effects are
orthogonal TOF systems where the ions are accelerated
perpendicularly to the initial extraction direction. These
instruments are typically equipped with a quadrupole filter
in front of the time-of-flight analyzer (QTOF) to allow
MS/MS experiments (Loboda et al. 2000). Mass accuracies
reported for MS imaging are in the range of 20–30 ppm
2 This parameter is also described as ‘bin size,’ ‘integration range’ or
‘mass window,’ The term ‘bin width’ will be used in this work.
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(Djidja et al. 2010). Applications of these systems include
drug compounds (Stoeckli et al. 2007a), peptides (Djidja
et al. 2009; Djidja et al. 2010; Trim et al. 2010) and lipids
(Prideaux and Stoeckli 2012; Trim et al. 2008). MALDI–
QTOF systems have also been combined with ion mobility
spectrometry separation (Stauber et al. 2010; Djidja et al.
2009). This method adds an additional gas-phase separa-
tion step (based on the collisional cross section), which can
help to resolve the complexity of biological samples.
The highest mass resolving power and mass accuracy
are obtained with Fourier transform ion cyclotron reso-
nance (FTICR) mass spectrometers (Marshall and Hend-
rickson 2002; Amster 1996; Marshall 2000; He et al. 2001;
Ro¨mpp et al. 2005). These analyzers have the advantage
that the cyclotron frequency (and thus the measured
m/z value) is independent of the kinetic energy of the ions.
This results in mass accuracies of better than 1 ppm which
can also be obtained in MS imaging experiments. FTICR
mass spectrometers have been used for MS imaging of
peptides (Taban et al. 2007) and drug compounds (Cornett
et al. 2008). Spatial resolution in these cases was between
200 and 300 lm. Sensitivity was lower than for regular
MALDI–TOF instruments. The combination of an FTICR
mass spectrometer with a MALDI imaging ion source at a
spatial resolution of 7 lm was demonstrated for artificial
targets by Koestler et al. (2008).
Development of the orbital trapping mass spectrometer
(Orbitrap, Thermo Fisher Scientific GmbH, Bremen, Ger-
many) greatly improved limits of detection (LOD) for
accurate mass measurements (Makarov 2000; Makarov
et al. 2006). This system is based on the detection of ions
trapped in an electrostatic field and does not require a
superconducting magnet. Apart from easier handling and
lower maintenance costs, this also allows for more efficient
ion transmission. Ions are accumulated in a so-called
C-trap which is located only centimeters away from the
analyzer cell. Orbital trapping mass spectrometers are
widely used in bioanalytical applications, typically coupled
to liquid chromatography (LC) systems by an electrospray
ionization source (ESI). They were also used to image
lipids (Landgraf et al. 2009) and peptides (Chen et al.
2010). Orbital trapping mass spectrometers were used for
all our measurements which are presented in this review.
Spatial resolution
Spatial resolution in MALDI imaging experiments pri-
marily depends on the size of the laser focus. While the
majority of MALDI imaging studies were performed at a
spatial resolution between 50 and 200 lm per pixel, there
are a number of notable exceptions. As mentioned above,
the first MALDI imaging results were obtained at 1 lm
pixel size (Spengler et al. 1994; Spengler and Hubert
2002). The obtained MS images showed in all detail the
spatial distribution of peptides and matrix compounds
(dihydroxybenzoic acid, DHB) in the crystals of a standard
MALDI preparation. The same system was used to image
cancer cells at 1 lm step size revealing the distribution of
several compounds up to m/z 5,000 (Bouschen et al. 2010).
A similar optical setup built by Bernhard Spengler was
used by Chaurand et al. (2007) to image proteins at 10 lm
pixel size. Recently MALDI imaging at 10 lm pixel size
using (slightly modified) commercial systems was dem-
onstrated for lipids (Thomas et al. 2012) and proteins
(Yang and Caprioli 2011).
The pixel size of the MS image is determined by the
distance that the sample is moved between two measure-
ments. This step size is usually chosen in the same range as
the laser focus diameter in order to avoid overlapping of
analyzed areas. An alternative is to move the sample by less
than the focus size resulting in ‘oversampling.’ If the laser
ablates all material of the sample, this method can generate
reasonable MS images with a pixel size that is several times
smaller than the laser focus size. This was demonstrated for
lipids at 15 lm pixel size (Snel and Fuller 2010) and for
peptides prepared from cells (Jurchen et al. 2005). It has to be
noted that oversampling improves pixel resolution on the cost
of sample loss. This is because a large-focus beam has a much
lower beam intensity slope at the focus edges than a small-
focus beam. The shallow intensity gradient significantly leads
to premature sample evaporation outside the ionization zone
and thus to a lower overall ion yield.
Another method of obtaining MS image pixels smaller
than the laser spot size is the so-called microscope mode
(Altelaar et al. 2007; Froesch et al. 2010; Luxembourg et al.
2004). In this case, the laser irradiates an area of 200 lm in
diameter and the ions are extracted and detected in a spatially
resolved manner. This method can deliver a pixel size of
about 4 lm, but practical issues such as detection speed make
it difficult to acquire MS imaging data over a larger mass
range with this technique (Stauber et al. 2008).
Mass spectrometry imaging with high resolution
in mass and space
MS images contain mass spectral and spatial information.
Consequently, data need to be acquired in high quality for
both dimensions. As described above, high spatial resolu-
tion and high mass resolution were achieved from MALDI
imaging experiments earlier, but only in separate experi-
ments. We have recently developed a method that for the
first time combines a spatial resolution in the low
micrometer range and high mass accuracy for the analysis
of biological samples. Phospholipids (Ro¨mpp et al. 2010a),
neuropeptides (Guenther et al. 2011) and drug compounds
(Ro¨mpp et al. 2011b) were imaged with accurate mass at a
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pixel size between 5 and 10 lm. Spatial resolution for
tryptic peptides after on-tissue digestion is lower, but
50 lm pixel size was demonstrated for this application
(Schober et al. 2012a). In all cases, this method provided a
significant improvement in spatial resolution and/or reli-
ability of identification compared to published methods as
discussed below.
Methodology
An important aspect in order to obtain high-quality and
reproducible results from tissue samples was to systemat-
ically evaluate and optimize every step of the analytical
workflow for the specific application. This included sample
selection, sample preparation, instrumental measurement
parameters, but also acquisition, processing and interpre-
tation of data. The following describes general aspects of
the workflow which are common to most of our studies.
More specific details and additional information are pro-
vided below in the individual sections covering the dif-
ferent applications.
Sample preparation
Tissue samples were snap-frozen immediately after the
animal was sacrificed and stored at -80 C. No embedding
or fixation was used. Thin sections of tissue with a thick-
ness of 10–20 lm were prepared with a microcryotome
(HM 525, Thermo Scientific, Dreieich, Germany) and
thaw-mounted on regular microscope glass slides. Con-
ductive coating of glass slides, indium tin oxide (ITO), is
not required, but was used in some applications. Tissue
sections were covered with matrix by a pneumatic sprayer
(Bouschen et al. 2010). 2,5-Dihydroxybenzoic acid (DHB)
at a concentrations of 30 mg/mL in acetone/water (0.1 %
TFA) 1:1 v/v was used as matrix solution. Matrix crystals
in the low micrometer range were obtained with this sys-
tem. Tissue sections were stained after the MS imaging
measurement in order to allow for a detailed analysis of
histological features. This included staining with hema-
toxylin and eosin (H&E), toluidine and Luxol fast blue
(Riedelsheimer et al. 2010).
Mass spectrometry imaging
Experiments were performed using a home-built atmo-
spheric pressure scanning microprobe matrix-assisted laser
desorption/ionization (AP-SMALDI) imaging source
attached to a linear ion trap/Fourier transform orbital
trapping mass spectrometer (LTQ Orbitrap Discovery,
Thermo Scientific GmbH, Bremen, Germany). The setup of
the AP-SMALDI imaging source is described in detail
elsewhere (Koestler et al. 2008). The source works at
atmospheric pressure and thus allows analyzing biological
samples in their native form without the need for dehy-
dration. A nitrogen laser (wavelength 337 nm) with a
repetition rate of 60 Hz was used. The laser beam was
focused onto the sample by a centrally bored objective
lens. In this system, the optical diameter of the focused
laser beam is 8.4 lm (as defined by a decrease in beam
intensities at the edges to 1/e2 (13.5 %) of its peak inten-
sity). The diameter of the ablation area (which defines the
effective spatial resolution) depends on the laser fluence on
the sample and is typically adjusted to 5 lm. A detailed
characterization of the optical system is described in
Guenther et al. (2010). The sample is moved in front of the
stationary capillary/lens setup by an x, y, z-stage with a
precision better than 1 lm. MS imaging data was acquired
with a mass resolving power of 30,000 at m/z 400 in profile
mode (i.e. mass peaks were not centroided for data
reduction). Ions from 30 laser pulses were accumulated in
the linear ion trap for each mass spectrum. Automatic gain
control (AGC) was disabled during the measurement, and
ion injection time was set to a fixed value (typically
650 ms). Mass accuracy was improved by applying inter-
nal calibration using the ‘lock mass’ feature of the Orbitrap
mass spectrometer. The dimer [2DHB - H2O ? H]
?, tri-
mer [3DHB - 2H2O ? NH4]
? and pentamer [5DHB -
4H2O ? NH4]
? of DHB were typically used as reference
masses for this procedure. This resulted in a mass accuracy
of better than 2 ppm (RMS) achieved for MS imaging
experiments of tissue. Mass spectrometer, laser and sample
stage are controlled and synchronized by a microcontroller
and home-built software. More details on the instrumental
setup and experimental parameters can be found in Ro¨mpp
et al. (2010a).
Software for image generation
MS images were generated by the software package MI-
RION (Paschke et al. submitted). The imaging software is
able to create ion images from any of the detected
m/z values with any selected mass window (bin width). MS
images can be generated semiautomatically based on a
number of selection parameters such as mass range and
pixel coverage. Alternatively selected ion images of a
defined m/z value can be generated manually. Up to three
different ion images are overlayed in red–green–blue
(RGB) images by the software to display different ion
species in parallel.
Reporting of MS images and mass spectral data
‘Images’ in mass spectrometry imaging are constructed in
the computer from individual mass spectra. Consequently,
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the information content of the resulting image can only be
as good as that of the underlying mass spectral data.
Therefore, we take extra care to ensure the quality and
validity of our reported MS imaging data. If not explicitly
stated differently, all data presented in this work adhere to
the following rules. Intensity values in selected ion images
were normalized to the highest intensity within the image,
measured for each ion species separately. MS images do
not include any spatial interpolation, smoothing or pixel-
wise normalization, in order to allow for an unbiased
evaluation. No overlay with optical images is used for MS
image presentation. Black-and-white images of selected
raw data are usually reported in the supporting information
of the original research publications. Step size of the stage
movement is identical in x and y direction, that is square
pixels are measured and displayed.
The terms ‘mass deviation,’ ‘mass accuracy’ and
‘maximum mass deviation’ are used according to the def-
inition by Zubarev and Mann (2007). All measurements are
based on high-resolution mass spectrometry data (mass
resolving power R [ 20,000 @ m/z 700), and images are
generated with a bin width of Dm/z = 0.01. In almost all
cases, this proved to be necessary in order to resolve the
complexity of biological samples. Mass spectra acquired
from single pixels are presented in order to allow an
evaluation of the quality of the underlying measurements.
Mass accuracy is not (solely) discussed on the basis of
selected mass spectra, but is reported as values of the root
mean square of m/z deviations across the whole imaging
measurement. Accurate mass measurements (RMS \
3 ppm) are used for assignment of imaged compounds.
Identification is confirmed by additional MS/MS experi-
ments whenever possible. All these factors are relevant in
order to report and evaluate the data in a reliable and
comprehensive way.
Phospholipids
Phospholipids are major structural components of all cell
membranes and play a crucial role in the cell metabolism
of all organisms. Phospholipid derivatives play an impor-
tant role in signal transduction and are thus of high rele-
vance for numerous pathological processes (Abrass 2004;
Lee et al. 2003). Changes in lipid metabolism are major
factors in diabetes and cancer (Paradisi et al. 2010; Santos
and Schulze 2012). Lipids have been analyzed by mass
spectrometry imaging in a number of studies (Sparvero
et al. 2010; Jackson et al. 2005; Benabdellah et al. 2009b;
Thomas et al. 2012).
The first application of our high-resolution mass spec-
trometry imaging method in the field of tissue analysis was
the analysis of phospholipids in mouse urinary bladder
(Ro¨mpp et al. 2010a). A measurement with 10 lm pixel
size is shown in Fig. 2a. The MS image shows excellent
agreement with classical histological information (after
toluidine staining, Fig. 2b). Certain phospholipid signals
could be clearly assigned to different tissue regions (all
lipids discussed here were detected as potassium adducts).
The outer region of the urinary bladder was found to be
characterized by the sphingomyelin compound SM (34:1)3
(m/z 741.5307, Fig. 2a, blue). This histological region
could be further subdivided into the adventitial layer, the
outermost thin layer as indicated by increased signal
intensities of SM (34:1) and the detrusor muscle mainly
consisting of smooth muscle tissue.
Following the muscle layer is the loose connective tissue
of the lamina propria, characterized by intense signals of
m/z 743.5482 (Fig. 2a, red). Colocalization with SM (34:1)
displayed in blue results in the magenta color of this region
in the RGB overlay. Toward the bladder lumen, a thin layer
of subepithelial myofibroblasts was found to be charac-
terized by again high signal intensities of SM (34:1)
(Fig. 2a, blue). The high cell densities of both layers were
expressed in the stained image (Fig. 2b). The innermost
layer of the mucosa is composed of the bladder epithelium
(urothelium), indicated by the phosphatidylcholine species
PC (34:1) at m/z 798.5410 (Fig. 2a, green). This discussion
shows that our MS imaging method can reproduce very
detailed histological features, close to cellular resolution.
In addition, it also provides highly reliable molecular
information.
A mass spectrum acquired from a single 10-lm pixel
from the urinary bladder imaging experiments is shown in
Fig. 2c. Several peaks are labeled based on accurate mass
measurements. Mass deviation of assigned peaks in this
spectrum was below or equal to 1 ppm. Mass accuracy as
determined over the whole measurement (10965 spectra)
was 0.6 ppm (root mean square of all mass deviations) for
PC (34:1) at m/z 798.5410. This demonstrates that accurate
mass detection is stable over the whole measurement under
imaging conditions. This is a prerequisite for reliable
identification of compounds and for specific image gener-
ation. Another important factor that influences MS image
quality is mass resolution. The effect of different bin
widths used for image generation is discussed in detail in
Ro¨mpp et al. (2010a), (Figure S5). MS images with
Dm/z = 0.01 result in complementary spatial intensity
distributions of two individual compounds, whereas a bin
width of Dm/z = 0.1 (which is often used in MS imaging
3 Lipids are denoted by the abbreviation for the respective compound
class followed by the total number of C atoms and the number of
double-bonds in the fatty acid chains. The chain lengths of the
individual fatty acid residues and the location of the double-bonds
cannot be resolved on the basis of accurate mass. This can be
achieved through additional MS/MS measurements.
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experiments) is not able to resolve this difference. This
example demonstrates the benefit of high mass resolution
and the importance of choosing the correct parameters for
image generation. A bin width of Dm/z = 0.01 is used
for all selected ion images shown in this work (except for
Fig. 6 where Dm/z = 0.02 is used).
A second measurement of the same urinary bladder
section (adjacent area) was measured with a pixel size of
5 lm. The selected ion images of two phospholipids in a
region of two adjacent tissue regions are shown in Fig. 2d.
This measurement also shows excellent agreement with
histological staining by toluidine (Fig. 2e). The MS image
provides sharp separation between the muscular layer
[m/z 741.5307, SM (34:1), green] and the urothel
[m/z 798.5410, PC (34:1), red]. These data demonstrate that
the effective analytical resolution is indeed in the range of
5 lm.
These results represented the first combination of high-
resolution, high-accuracy mass spectrometry with a pixel
size in the low micrometer range for mass spectrometry
imaging of biological samples. Both features are necessary
in order to obtain reliable molecular information from
tissue sections on a cellular level. These results also show
that phospholipids are highly specific for different cell
types and can thus provide detailed histological
information. This information can be used to differentiate
and assign features in tissue section which might not be
apparent when using classical histological techniques.
Drug compounds
Detection of drug compounds is a major application of
mass spectrometry imaging (Prideaux and Stoeckli 2012).
The ability for label-free detection of and differentiation
between drug compounds and metabolites are its major
advantages compared to autoradiography, which is the
routine method to investigate the spatial distribution of
drug compounds in animal models (Solon et al. 2010). The
spatial resolution in MS imaging measurements of drug
compounds typically has been in the range of 200–500 lm,
which is sufficient to analyze whole body sections (Khatib-
Shahidi et al. 2006; Stoeckli et al. 2007a) or individual rat
organs (Cornett et al. 2008), but insufficient to resolve
detailed features in mouse organs. The highest spatial
resolution reported before for drug compounds was
100 lm (Acquadro et al. 2009; Stoeckli et al. 2007a). MS
imaging experiments with accurate mass detection for drug
compounds were performed at 350 lm spatial resolution
(Cornett et al. 2008). Drug compounds are usually detected
Fig. 2 Mouse urinary bladder a MS image, 10 lm pixel size,
260 9 130 pixels, blue muscle tissue, SM (34:1), [M ? K]?,
m/z 741.5307, green urothelium, PC (34:1), [M ? K]?,
m/z 798.5410, red lamina proria, m/z 743.5482. b Optical image of
same tissue section after staining (toluidine blue). c Mass spectrum
acquired from a single 10-lm pixel. d MS image, 5 lm pixel size,
260 9 130 pixels (detail of larger measurement): blue substrate,
Indium cation, m/z 114.9039, red PC (34:1), [M ? K]?,
m/z 798.5410, green SM (34:1), [M ? K]?, m/z 741.5307. e Optical
image of same tissue section after staining (toluidine blue). Modified
from original figure by Ro¨mpp et al. (2010a). Copyright  2010
WILEY–VCH Verlag GmbH & Co. KGaA, Weinheim
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in MS/MS mode in order to increase the specificity of the
measurement and to prevent interference of matrix cluster
ions which are typically abundant in the low mass range
(Stoeckli et al. 2007a). The number of compounds that can
be detected in one experiment is limited in this approach.
Following the promising results on phospholipids, we
investigated the distribution of drug compounds by ‘mass
spectrometry imaging with high resolution in mass and
space (HR2 MSI)’ (Ro¨mpp et al. 2011b). The anticancer
drug imatinib (a tyrosine kinase inhibitor) was analyzed in
mouse kidney at 35 lm pixel size. Selected ion images of
phospholipids are shown in Fig. 3a. The distribution of
these phospholipids corresponds very well to histological
features of the kidney as determined by H&E staining
(Fig. 3c). The distribution of the drug compound imatinib
in the mouse kidney is shown in Fig. 3b. Imatinib
([M ? H]?, m/z 494.2662) is displayed in green, while two
phospholipids (red and blue) are included to indicate the
histological features of the kidney. Identification and
structural characterization of tissue regions, which usually
requires examination of the H&E-stained section by a
trained histologist, is possible based on the MS imaging
data of lipids. This information can be used to determine
the exact location of the targeted analyte in the mouse
kidney. The colocalization of imatinib (Fig. 3b, green) and
PC (40:6) (Fig. 3a, blue) indicates that imatinib is accu-
mulated in the outer stripe of the outer medulla.
A mass spectrum acquired from a single 35-lm pixel is
shown in Fig. 3d. The molecular ion peak ([M ? H]?) of
imatinib was detected with a mass deviation of -0.4 ppm
and a mass resolution of R = 30,000 in this spectrum.
The overall mass accuracy for imatinib in the imaging
Fig. 3 Mouse kidney a overlay of selected ion images: green [PC
(32:0) ? K]? = 772.5253 cortex, blue [PC (40:6) ? K]? =
872.5566 outer stripe outer medulla, red [PC (38:5) ? K]? =
846.5410 inner stripe outer medulla, 225 9 150 pixels, 35 lm step
size, bin width Dm/z = 0.01; b overlay of selected ion images: red
[PC (32:0) ? K]? = 772.5253, green imatinib [M ? H]? =
494.2662, blue [PC (34:1) ? H]? = 760.5851, 225 9 150 pixels,
35 lm step size, bin width Dm/z = 0.01; c optical image of the
investigated mouse kidney section, H&E stained after MS imaging
measurement; d single-pixel mass spectrum of the outer stripe outer
medulla of the mouse kidney section. Reprinted from Ro¨mpp et al.
(2011b)
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measurement calculated from 5862 individual spectra was
2 ppm (root mean square of mass deviations in all spectra).
The identity of imatinib was verified by additional MS/MS
experiments, which showed a characteristic fragmentation
pattern.
A smaller area of an adjacent mouse kidney section was
imaged with 10 lm pixel size in order to investigate the
distribution of imatinib in more detail. The resulting MS
images again showed excellent agreement with histological
features of the mouse kidney and confirmed that imatinib is
specifically accumulated in the outer stripe of the outer
medulla [see Ro¨mpp et al. (2011b) for details]. This can be
tentatively associated with a selective accumulation of drug
molecules in the proximal tubules. Imatinib was detected
with a mass accuracy of 1.8 ppm RMS (calculated from
5816 individual spectra) in this 10 lm measurement.
Mass spectrometry imaging with high resolution in mass
and space (HR2 MSI) provides detailed information on
spatial distribution of compounds. The described mea-
surements represented the first mass spectrometric imaging
analysis of drug compounds at 10 lm pixel size. This
constituted a 10-fold increase in spatial resolution com-
pared to previous studies. At the same time, the measure-
ments provided detailed information on histological
features based on the spatial distribution of phospholipids
and other endogenous compounds. Correlation of different
images allowed for fast and easy interpretation of the drug
compound distribution, and areas of accumulation could be
directly linked to certain tissue regions.
Neuropeptides
Neuropeptides are important messenger molecules that
control a wide range of regulatory functions and processes
within an organism. They are formed in vivo by cleavage
of precursor proteins and often undergo posttranslational
modifications (PTM). These modifications directly affect
the biological function of neuropeptides. Investigation of
neuropeptides therefore requires specific detection and
reliable identification. This can be difficult with histo-
chemical methods as antibodies are not always able to
differentiate PTMs. Previous MS imaging approaches for
neuropeptide analysis included high spatial resolution
(Altelaar et al. 2006, 2007), high mass resolving power and
mass accuracy (Taban et al. 2007; Chen et al. 2010) or
MS/MS capabilities (Chen et al. 2009; Verhaert et al. 2007;
DeKeyser et al. 2007), but these features were never
combined in one experiment.
Therefore the aim of our study (Guenther et al. 2011)
was to demonstrate that MS imaging of neuropeptides in
mammalian tissue is possible with high mass resolution
and with MS/MS analysis at cellular resolution. The
pituitary gland is one of the best known neuropeptide-
secreting organs in mammals and was therefore chosen for
our experiments. It consists of three distinct histological
regions, called anterior, posterior and intermediate lobe.
Each of these regions has different functions and produces
different neuropeptides. In a first experiment, a section
of a complete mouse pituitary gland (approximately
1.5 mm 9 2.5 mm) was imaged at a pixel size of 10 lm
using a mass range of m/z 200–4,000. Figure 4 shows the
optical image (a) and examples for MS images of neuro-
peptides (b–d). The distribution of phosphatidylcholine PC
(38:4) (shown in green) was used to indicate the overall
shape of the pituitary gland. Neuropeptides originating
from the same precursor were found to be colocalized. For
example, vasopressin and two variants of copeptin, which
are all formed from the prohormone AVP-NPII, were
detected in the posterior lobe. The neuropeptides POMC
76–85 (c-MSH), POMC 103–120 (joining peptide), POMC
124–136 (a-MSH) and POMC 141–162 (CLIP) were
detected in the intermediate lobe, where the corresponding
prehormone POMC is known to be synthesized. In addi-
tion, two modifications of a-MSH, the acetylated and
diacetylated forms, were detected in this region. This
demonstrates that posttranslational modification of neuro-
peptides can be differentiated with our method. The
determined spatial distributions of all detected neuropep-
tides were in agreement with their expected biological
function. In total, 10 neuropeptides were detected in this
measurement.
A single-pixel (10 lm) mass spectrum acquired from
the intermediate lobe is shown in Fig. 4e. Peptides were
identified by comparing their accurate mass with theoreti-
cal values for known neuropeptides. A maximum mass
tolerance of 2 ppm was used for this procedure. The
identity of the neuropeptides was confirmed by additional
MS/MS measurements which were obtained in profiling
mode from selected areas of the pituitary gland. The
identification of all 10 neuropeptides was confirmed by
detailed evaluation of product ion peaks [see Guenther
et al. (2011) for details]. Furthermore, the spatial distri-
bution of two peptides was investigated by MS/MS in
imaging mode at 10 lm spatial resolution. The resulting
product ion images were in excellent agreement with the
distributions of their peptide precursor ions, confirming
their identity and excluding possible analyte interferences.
In an attempt to resolve the fine structure of the pituitary
gland, a smaller area covering all three lobes (indicated by
a yellow square in Fig. 4b) was imaged at 5 lm pixel size.
An overlay of selected ion images of the neuropeptides is
shown in Fig. 4f. Diacetyl-a-MSH (POMC 124–136) was
found to be located in the intermediate lobe (green).
Vasopressin (AVP-NPII) was detected in the center of the
posterior lobe (blue). Oxytocin (OT-NPI 20–28) was also
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present in the posterior lobe, but was primarily detected in
the outer region of this lobe. The different distributions of
these two peptides are in agreement with the known origin
of the corresponding prehormones and can be directly
linked to physiological processes on a cellular level [see
Guenther et al. (2011) for details].
This study demonstrated that MS imaging of neuro-
peptides in mammalian tissue is possible at cellular reso-
lution. For the first time, such experiments were performed
by combining accurate mass analysis, high mass resolving
power and high spatial resolution in one experiment.
Peptide sequences were verified by MS/MS experiments,
including posttranslational modifications which cannot be
differentiated by antibody staining methods.
Proteins (on-tissue tryptic digestion)
Proteins are one of the most studied compound classes in
biomedical applications. The analysis of their spatial
distributions can provide additional information about
their role in physiological and pathological processes.
Numerous studies have been published on MS imaging
of proteins (Chaurand et al. 2007; Leinweber et al. 2009;
Rauser et al. 2010a, b; Shimma et al. 2008; Walch et al.
2008). Spatial resolution for proteins is typically in the
range of 100–250 lm. A recent study showed measure-
ments at 10 lm pixel size (Yang and Caprioli 2011).
However, protein analysis by MS imaging still faces a
number of problems (McDonnell et al. 2010). Direct
Fig. 4 Mouse pituitary gland. a Optical image of mouse pituitary
gland tissue section, b, c, d overlay of selected peptide ion images
(see label below images) with selected ion image of PC (38:4)
(green), 155 9 255 pixels, pixel size was 10 lm. e Single-pixel mass
spectrum from intermediate lobe. f Overlay of selected peptide ion
images, 100 9 140 pixels. Pixel size 5 lm. Yellow square in
b indicates the location of the measured region. Modified from
original figure by Guenther et al. (2011)
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analysis under imaging conditions is typically limited to
proteins below 30 kDa (Francese et al. 2009), but can be
increased in some cases by improved sample preparation
techniques (Franck et al. 2010; Leinweber et al. 2009)
and/or instrumental modifications (van Remoortere et al.
2010). A major drawback of most studies is that protein
signals are not identified, but merely reported as
m/z values. This limitation significantly reduces the
relevance of reported results for many biomedical
applications. Identification of intact proteins from tissue
is difficult due to the often limited mass resolution which
is insufficient to resolve the complexity of tissue sam-
ples. Tandem MS is also of limited use as isolation, and
fragmentation efficiency is low for large proteins. Pro-
teins in tissue can be tentatively identified in some cases
by additional LC–MS/MS measurements and validated
by specific antibodies (Rauser et al. 2010b; Balluff et al.
2010).
An alternative approach is to digest proteins directly on
tissue and to image the distribution of the resulting tryptic
peptides (Groseclose et al. 2007; Lemaire et al. 2007a).
Peptides are easier to detect and identify than the intact
proteins, due to their lower molecular weight. This tech-
nique has been used for the analysis of tumor samples and
other tissue types (Cazares et al. 2009; Djidja et al. 2010).
Another advantage of enzymatic digestion is that formalin-
fixed paraffin-embedded (FFPE) tissue can be analyzed
(Casadonte and Caprioli 2011; Gustafsson et al. 2010;
Lemaire et al. 2007a). However, most of these results are
still limited to highly abundant proteins (Debois et al.
2010). Typically no more than a few tens of peptides are
identified by direct MS/MS measurements (while much
more potential peptide peaks are detected). This is due to
the limited fragmentation efficiency of singly charged ions,
which are produced in MALDI almost exclusively, and to
ion suppression effects in the complex matrix of tissue
sections.
These limitations can be overcome by a combination of
MS imaging with liquid chromatography coupled to mass
spectrometry (LC–MS). In this method, one tissue section
is analyzed by MS imaging, while an adjacent section is
homogenized and analyzed by LC–MS/MS. This approach
has recently been applied to lipids (Burnum et al. 2009;
Monroe et al. 2008), peptides (Altelaar et al. 2007; Monroe
et al. 2008) and proteins (Rauser et al. 2010b; Stauber et al.
2008; Gustafsson et al. 2010). Linking these two modalities
is, however, challenging due to the high complexity of the
analyzed biological samples (mainly mammalian tissue
sections).
The following two sections describe a method for reli-
able identification of tryptic peptides based on accurate
mass measurements followed by an approach to improve
spatial resolution.
High mass accuracy MS imaging of tryptic peptides
on tissue
The goal of our first study involving tryptic peptides was to
improve the reliability of identification by acquiring mass
spectra with accurate mass (Schober et al. 2011). In addi-
tion, a combination of on-tissue tryptic digestion and
complementary LC–MS/MS analysis of the corresponding
proteome was applied to increase the number of identified
peptides. The highest mass accuracy reported earlier for
imaging of tryptic peptides was 30 ppm on a time-of-flight
system (Djidja et al. 2010), while most studies reported
values in the range of 100 ppm.
In our study, trypsin solution was deposited manually on
mouse brain tissue resulting in trypsin spots of about 1 mm
diameter (Schober et al. 2011). MS images at a pixel size of
100 lm were acquired from the mouse brain section. In
contrast to the other MS imaging experiments discussed in
this work, these sections were analyzed with the com-
mercial MALDI source manufactured by Thermo Fisher
Scientific (Bremen, Germany). Selected ion images of two
peptides are shown in Fig. 5a, b. In the next step, a mouse
brain tissue section, adjacent to the one used for MALDI
imaging, was analyzed by LC–ESI–MS/MS in order to
identify proteins which are present in this tissue. Prior to
analysis, this sample was homogenized and fractionated by
ultracentrifugation resulting in four subcellular fractions:
cytosol, mitochondria/nuclei, endoplasmatic reticulum/
golgi and plasma membranes. More than 1,100 peptides
corresponding to 500 proteins were identified in this sam-
ple. The data from MALDI imaging (tissue section) and
from the LC–ESI–MS/MS experiment (homogenate sam-
ple) were combined as shown in Fig. 5c, d. In analogy to
our previous work (Ro¨mpp et al. 2007), a maximum mass
deviation of 3 ppm between m/z values of MALDI imaging
peaks and masses of peptides identified by LC–ESI–MS/
MS was accepted in this study. The two peaks detected by
MALDI imaging (Fig. 5c) match with masses of peptides
that were identified in the mouse brain tissue by LC–ESI–
MS/MS (Fig. 5d). Therefore, the corresponding images
were assigned to these two peptides. An unequivocal match
of MALDI imaging and LC–ESI–MS/MS data is only
possible with a mass accuracy in the low ppm range for
both measurement modes, while less accurate measure-
ments would lead to ambiguous assignments. For example,
at 30 or 100 ppm mass tolerance, more than one possibility
of linking the two measurements existed and would have
obstructed an unequivocal interpretation of imaging results
[see Schober et al. (2011) for details].
The combination of MALDI imaging and LC–ESI–MS/
MS led to the identification of more than 147 peptides
corresponding to 101 proteins. More than 75 % of these
proteins had a molecular weight of more than 30 kDa and
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would therefore not be accessible for a top-down approach
imaging intact proteins directly on tissue. A total of 24
proteins were detected with two or more peptides and could
be considered as reasonable matches. These numbers are in
line with comparable studies (Djidja et al. 2009; Gustafs-
son et al. 2010), but the reliability of identification is sig-
nificantly higher in our measurements due to accurate mass
data.
This study showed that the identification of tryptic
peptides without accurate mass and without comple-
mentary approaches such as bulk identification methods
can easily produce misleading results. In light of these
results, the identification results of previous studies have
to be considered with care if no independent histo-
chemical confirmation was performed. In particular, in
the case of digested tissue sections of high complexity,
reliable identification of proteins significantly benefits
from high mass accuracy of measurements. This proof-
of-concept study was based on low-spatial-resolution
imaging. Results and implications with respect to accu-
rate mass measurements are, however, equally relevant
for experiments with smaller trypsin spots as demon-
strated in the following section.
Improved spatial resolution for MS imaging of tryptic
peptides
The second study on MS imaging of tryptic peptides
(Schober et al. 2012a) was focused on increasing the
accessible spatial resolution while maintaining the high
reliability of the identification step. The critical step in
increasing spatial resolution for tryptic peptides is the
application of the enzyme solution (usually trypsin). In
most of the reported studies, trypsin was deposited in dis-
crete positions by a spotting device (Groseclose et al. 2007;
Stauber et al. 2008). Only recently, homogeneous appli-
cation of trypsin by a spraying device has been reported
(Djidja et al. 2010). The spatial resolution of studies
reported so far was typically in the range of 200–250 lm.
The smallest pixel size for MS imaging of tryptic peptides
reported earlier was 150 lm (Stauber et al. 2010).
In our study, trypsin was deposited by a spraying device
similar to that used for matrix application (Bouschen et al.
2010). All parameters of sample preparation were carefully
optimized (Schober et al. 2012a). Trypsin was deposited in
several aliquots (of 3 lL each) in intervals of 15 min,
preventing excessive accumulation of liquid on the tissue.
The sample was placed in an incubator (37 C, 100 %
relative humidity) between spraying cycles and was incu-
bated overnight after the last trypsin deposition. Another
important factor is the employed buffer solution,
NH4HCO3, which proved to be compatible with subsequent
matrix application. We also used a trypsin concentration
that was twice as high as in most published studies. The
resulting tryptic peptides in a mouse brain section were
analyzed by mass spectrometry imaging at 50 lm pixel
size. Peptides were identified by comparison with LC–ESI–
MS/MS as described above [see Schober et al. (2011)]. One
of the first measurements using this new approach is shown
in Fig. 6. The mass spectrum acquired from a single 50-lm
pixel shows two peaks at nominal mass m/z 726 (Fig. 6a).
The myelin peptide HGFLPR (theoretical m/z 726.4046)
was detected with a mass deviation of -0.28 ppm and a
mass resolution of R = 24,000 in this spectrum. The
overall mass accuracy for this peptide in the imaging
measurement calculated from more than 500 individual
spectra was 1.0 ppm (root mean square of all mass devia-
tions). Another signal at the same nominal mass was
detected at m/z = 726.5114 and was discriminated from
the myelin peptide signal. This second peak was identi-
fied as an isotopologue peak of the ammonium adduct
of the lipid phosphatidylserine PS (30:0) (theoretical
Fig. 5 a, b Selected ion images of two identified peptides with an
imaging bin width of Dm/z = 0.01. c Section of the averaged mass
spectrum of high mass accuracy MS imaging of mouse brain tissue,
containing two identified tryptic peptides. d m/z values of all tryptic
peptides identified in homogenate LC/ESI–MS/MS measurements in
the displayed mass range (m/z 1,256.50–1,256.75). Modified from
original figure in Schober et al. (2011). Copyright  2011 John Wiley
& Sons, Ltd
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m/z 726.5128). Fig. 6d shows a selected ion image gener-
ated with a bin width of Dm/z = 0.2. In this image, no
differentiation between the peptide and the lipid isotopo-
logue was possible; the myelin peptide signal was masked
by the lipid isotopologue. Figure 6c, e show selected ion
images generated with a bin width of Dm/z = 0.02 for the
myelin peptide and the lipid isotopologue, respectively. In
this representation, both analyte distributions were clearly
resolved.
The myelin peptide shows a well-defined distribution
with high intensities in the corpus callosum area of the
mouse brain which is in accordance with its physiological
function (Sidman 2011). Figure 6b shows the optical image
of an adjacent mouse brain section after staining of the
myelin sheath (Luxol fast blue). The myelin distributions in
the MS image and the histological staining show excellent
correlation. This confirms that the spatial distribution of
myelin was preserved and no substantial migration of
tryptic peptides occurred during the digestion process.
A similar measurement with a higher number of iden-
tified peptides is discussed in Schober et al. (2012a). In
total, 9 peptides corresponding to myelin and 19 peptides
corresponding to other proteins were identified and imaged.
All myelin peptides showed well-defined distributions
which were highly correlated with each other. The number
of identified peptides in this work is in the same range as
that of studies reported in the literature (Groseclose et al.
2007; Franck et al. 2009; Shimma et al. 2008), but was
obtained at significantly smaller pixel size. Peptides were
also identified with a very low mass tolerance of 3 ppm and
thus with higher confidence.
These measurements represented the first MS imaging
experiment of tryptic peptides with a spatial resolution of
50 lm. The small pixel size shown here cannot be achieved
with spotting devices since the size of individual droplets
and thus the resulting trypsin spots are too large. Diffusion
processes within these trypsin spots on tissue lead to
unwanted spreading of peptides. The homogeneous appli-
cation of trypsin by a spraying device can overcome this
problem if spraying conditions such as flow rate, distance
and buffer solution are carefully controlled. As for all MS
imaging experiments, sample preparation and instrumental
parameters have to balance analytical sensitivity and spatial
resolution. The experiments in this study were optimized
for ultimate spatial resolution. Exact conditions need to be
optimized for each tissue type and targeted application.
The obtained results represented a significant improve-
ment over previously reported methods in terms of image
quality for tryptic peptides. The improved spatial resolution
made smaller histological features accessible. High mass
resolving power improved the specificity of the spatial
distribution information by reducing interferences with
neighboring peaks. Accurate mass allowed for reliable
identification of tryptic peptides. Each of these factors was
Fig. 6 Mouse brain (coronal
section) after on-tissue tryptic
digestion. a Mass spectrum
from a single 50-lm pixel.
b Optical image of adjacent
section after staining for myelin
(Luxol fast blue) c, d, e MS
images, 50 lm pixel size,
92 9 128 pixels: c selected ion
image of m/z = 726.40–726.41
corresponding to myelin
peptide. d Selected ion image of
m/z = 726.40–726.60.
e Selected ion image of
m/z = 726.51–726.52
corresponding to lipid
isotopologue peak. Details on
method can be found in Schober
et al. (2012a)
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found to be critical in order to obtain reliable information
on biologically relevant compounds. The capabilities of the
method were demonstrated in a proof-of-concept study on
mouse brain tissue.
Current experiments demonstrate that comparable
results in terms of reliable identification can also be
obtained from clinical tissue samples. Newest develop-
ments also indicate that the number of identified peptides
can be significantly increased and that spatial resolution
can most likely be further improved.
Single-cell MALDI imaging
Cell cultures are a common model system in biological and
biomedical research. The influence of pathogenic and/or
environmental factors can be studied under controlled
conditions. Metabolic studies in cell cultures are usually
based on the analysis of bulk samples. The analysis of
individual cells would instead provide much more specific
and informative data. Previous attempts to use MS imaging
for this application faced a number of problems. Time-of-
flight secondary ion mass spectrometry (TOF-SIMS) offers
sub-micrometer spatial resolution and is able to image the
spatial distribution of metabolites inside single cells (Col-
liver et al. 1997; Ostrowski et al. 2004). However, TOF-
SIMS in single-cell analysis is typically limited in mass
range to m/z\ 500, and detected analytes can often not be
identified (Szakal et al. 2011). This is due to severe frag-
mentation of analyte ions and limited MS/MS capabilities
in imaging mode. MALDI imaging, in contrast to that,
offers higher mass range and higher mass resolution.
However, direct analysis of single cells with this method
resulted in only one pixel per cell due to the limited spatial
resolution of 40–50 lm in reported studies (Miura et al.
2010; Zimmerman et al. 2011).
Based on the instrumentation and methodology descri-
bed above, we developed a dedicated workflow for imaging
metabolite distribution in single cells (Schober et al.
2012b). Sample preparation is a critical step in obtaining
useful results in mass spectrometry imaging, especially at
high spatial resolution. Fixation methods with ethanol or
formaldehyde resulted in the loss of the cells during sample
preparation. The best results for analysis with MALDI MS
imaging were obtained by fixation of cells with glutaral-
dehyde. Experimental details such as temperature of solu-
tions, buffer concentration and incubation times proved to
be critical and were carefully optimized. After fixation,
cells were stained with 3,30 dihexyloxacarbocyanine iodide
[DIOC6(3)], which is a fluorescence dye that stains cell
membranes (Invitrogen 2011). After matrix application,
samples were measured with our AP-SMALDI ion source
on an ‘Exactive Orbitrap’ mass spectrometer (Thermo
Fisher Scientific GmbH, Bremen, Germany). This system
provided improved sensitivity and mass resolution
(R = 100,000 @ m/z 200) compared to the previously used
‘LTQ Orbitrap.’
The images of two individual HeLa cells are shown in
Fig. 7. The signal of DIOC6(3) in optical fluorescence mode
(wavelength k = 501 nm, Fig. 7a) and MS imaging mode
(selected ion image of m/z 445.285, Fig. 7b) show very good
correlation. The shape of the cells is clearly visible in the MS
image, and their extensions of only a few micrometers in
diameter are detectable. This implies that the spatial struc-
ture of the cells was not affected significantly by matrix
application and the measurement procedure. Figure 7c, d
show selected ion images of two phospholipids. The
(sodium adducts of) phosphatidylcholines PC (16:0/16:1)
and PC (16:0/18:1) were detected primarily in the center of
the cell where higher concentrations of membranes are
expected. The fatty acid chain length of these two phos-
pholipids was determined by additional MS/MS experi-
ments [see Schober et al. (2012b) for details].
A mass spectrum acquired from a single 7-lm pixel is
shown Fig. 7e. Numerous phospholipids such as phospha-
tidylcholine (PC), sphingomyelin (SM), phosphatidylserine
(PS), as well as di- (DG) and triglycerides (TG) were found
in the mass range m/z 620–810. As in all our studies, the
imaged compounds were detected with accurate mass
(better than 3 ppm RMS for the complete image) and
therefore allow reliable substance identification. In addition
to phospholipids, smaller metabolites such as nucleic acids,
amino acids as well as cholesterol were identified in the
lower mass range [see Schober et al. (2012b)]. A broad
metabolic profile could thus be acquired from a defined
area of the cell with high confidence. Alternatively, several
spectra acquired from one cell can be combined in order to
obtain better statistics for quantitative analysis.
Current experiments focus on the mass range of phos-
pholipids. Invasion mechanisms of pathogens are known to
lead to changes in the lipid pattern through enzymatic
degradation (Vazquez-Boland et al. 2001). These effects
can be investigated with high molecular specificity in sin-
gle cells at different stages of the infection process with the
methodology described here. Another application that is
currently evaluated is monitoring the differentiation of
stem cells on a molecular level. In general, our method can
be used for a detailed investigation of metabolic changes in
single cells and can provide more detailed and/or more
reliable information than previous MS imaging approaches.
Analysis of lung carcinoma tissue
We typically test our methodology with mouse brain tissue
as this is a widely used model system for MS imaging. The
Histochem Cell Biol (2013) 139:759–783 773
123
molecular composition of this tissue is well known, and
extensive histological information is available in brain atlas
resources (Sidman 2011; Hochheiser and Yanowitz 2007).
Once a certain method is optimized, it is applied to more
relevant samples including clinical tissue sections. An
example that was first shown in a conference presentation
(Ro¨mpp et al. 2011a) is the analysis of a human non-small-
cell lung carcinoma that was induced into a severe com-
bined immunodeficiency (SCID) mouse model (Fig. 8).
This tissue section was imaged at 10 lm pixel size. MS
image analysis (Fig. 8a) shows excellent correlation with
the different regions within the cancerous tissue that were
identified by the pathologist in the H&E staining (Fig. 8b).
Cerebroside Cer (42:2) (Fig. 8a, green) was found to be
almost exclusively present in the connective tissue of this
section. The tumor region can be further differentiated in
the invading tumor edge with high signal intensities of
phosphatidylcholine PC (32:1) (Fig. 8a, blue) and the
ischemic tumor region that was characterized by high
signal intensities of phosphatidylcholine PC (40:6)
(Fig. 8a, red). Purple color results from colocalization of
PC (32:1) (blue) and PC (40:6) (red). Multiple other lipid
species were detected and identified for each tissue region
in addition to the examples shown here. Figure 8c shows
the distribution of lyso-phosphatidylcholine LPC (16:0)
(green), primarily localized in the area of the tumor that
was identified as necrotic zone. Lyso-lipids are degradation
products of lipids and are therefore expected in areas where
cell degradation occurs. This is another example where our
method provides more insights about the molecular infor-
mation that is not directly accessible by classical histo-
logical methods. This approach can be applied to
investigate the molecular processes in tumorigenesis and to
differentiate tumor states.
Lipids in this measurement were identified by accurate
mass data. As demonstrated above for tryptic peptides
(Fig. 6), the bin width used for image generation signifi-
cantly affects the result of an MS imaging experiment.
Generating MS images with a bin width of m/z = 0.1, as
common for many MALDI–TOF measurements, would
result in the distribution shown in Fig. 8d. However, the
healthy and tumor tissue regions can only be differentiated
by using a bin width of Dm/z = 0.01 (Fig. 8e, f). These
black-and-white images represent the raw data acquired
from the mass spectrometer without applying any pro-
cessing steps. Overlay of these two signals shows very
sharp separation between (healthy) connective tissue and
the tumor region (Fig. 8g). Similar effects were observed
for nearly all signals in the lipid mass region. Conse-
quently, the reliable characterization of complex samples
such as mammalian tissue sections by mass spectrometry
imaging greatly benefits from the use of high-resolution
mass spectrometry.
MALDI imaging at 3 lm pixel size
In an attempt to further improve the accessible spatial
resolution of MALDI imaging, the lateral ventricle region
of a coronal mouse brain section was imaged with 3 lm
pixel size. The MS image of this experiment, which was
included in a conference presentation (Ro¨mpp et al.
2010b), is shown in Fig. 9a. The selected ion image of
phosphatidylcholine PC (38:4) shows the detailed structure
Fig. 7 HeLa cells on ITO-coated glass slide. a Optical fluorescence
of DIOC6(3)-stained HeLa cells (k = 501 nm). b, c, d MALDI
imaging, 7 lm pixel size, 28 9 21 pixels (detail of larger measure-
ment): b selected ion image of staining agent DIOC6(3), [M]?,
c selected ion image of phosphatidylcholine PC (32:1), [M ? Na]?
and d selected ion image of PC (34:1), [M ? Na]?. e Single-pixel
mass spectrum (7 lm) acquired from the region of cell nucleus.
Reprinted with permission from (Schober et al. 2012b). Copyright
2012 American Chemical Society
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of the choroid plexus (green), while the surrounding tissue
is characterized by high intensities of phosphatidylcholine
PC (34:1). The optical image of the tissue sample prior to
MS analysis is shown in Fig. 9b. The poor quality of the
optical image is due to the fact that the sample is com-
pletely consumed under these highly focused laser condi-
tions, and subsequent staining of tissue was therefore not
possible. The quality of the mass spectral data is, however,
not significantly affected by the reduction in pixel size. A
mass spectrum acquired from a single pixel (corresponding
to 3 9 3 lm2 tissue area) is shown in Fig. 9c. Phospho-
lipids in this mass spectrum were detected with a mass
deviation of \2 ppm and a mass resolution of about
R = 20,000. Lower signal intensities make recalibration
based on matrix cluster signals slightly more challenging in
this experiment. These measurements demonstrate that
under slight oversampling conditions (at an ablation spot
diameter of 5 lm in diameter) still high-quality mass spec-
tral data can be obtained in high-resolution AP-SMALDI
imaging and that there is still potential for a further increase
in spatial resolution.
Spatial resolution and measurement speed
It is often argued that imaging at high spatial resolution takes
too much time. This might be true if two experiments of the
same measurement area are compared. But high spatial res-
olution imaging is typically targeted at smaller structural
features which would not be resolved otherwise. Therefore,
the spatial resolution (pixel size) of an experiment should be
adjusted according to the structure of interest. The speed of
our method of about 1 s per pixel is comparable to that of
other mass spectrometry imaging systems. Recent experi-
ments indicate that significant increase in speed can be
obtained (with almost constant mass accuracy and moderately
lower mass resolution). At present, our method already pro-
vides reliable MS imaging measurements at different spatial
resolution settings as demonstrated in Fig. 10. All three MS
images show detailed histological features (at different spatial
scales). Figure 10a shows the phospholipid spatial distribu-
tion in mouse brain (coronal section) at 5 lm pixel size. The
structure of the putamen and the corpus callosum (upper
right) are clearly visible. Figure 10b shows a horizontal
Fig. 8 Human non-small-cell
lung carcinoma that was
induced into a severe combined
immunodeficiency (SCID)
mouse model. a MS image,
10 lm pixel size, 185 9 185
pixels, red sphingomyelin SM
(36:1), m/z 769.5620, green
cerebroside Cer (42:2),
[M ? K]?, m/z 848.6376, blue
phosphatidylcholine PC (36:4),
[M ? K]?, m/z 820.52531.
b H&E staining after
measurement. c MS image,
10 lm pixel size, 185 9 185
pixels, green lyso-
phosphatidylcholine LPC
(16:1), [M ? H]?,
m/z 496.3397, red
phosphatidylcholine PC (38:6)
[M ? K]?, m/z 844.5253. d, e,
g Selected ion images generated
with different settings for image
generation as indicated in
Figure
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section of mouse brain at 50 lm pixel size. The two imaged
phospholipids show detailed features in the corpus callosum,
striatum and cerebellum region. Figure 10c shows a mea-
surement of the intestinal tract of a whole body rat section at
200 lm pixel size. A phospholipid (red) that provides histo-
logical information can be directly used to indicate the
localization of a drug compound (green) [see Ro¨mpp et al.
(2011b) for details]. A useful approach for balancing mea-
surement time and spatial information is to scan a larger area
with lower spatial resolution in order to identify areas of
interest. These areas can then be scanned with higher spatial
resolution in order to investigate the detailed distribution of
analytes.
Measurement speed is obviously an important factor
when comparing quantitative differences between two
biological conditions. In this case, biologically relevant
results can only be obtained if the experiment is repeated
with several samples (biological replicates). Consequently,
higher speed allows for a higher number of measurements
and thus provides more reliable results. Another approach
is the detailed molecular analysis of a (tissue) sample
without prior knowledge. In such an untargeted approach,
data analysis and interpretation can be much more time-
consuming than the actual measurement itself. In this case,
specificity and sensitivity of the measurement is of highest
priority and measurement speed is of less importance.
Data analysis: imzML—a common data format for MS
imaging
Mass spectrometry imaging produces large and complex
data sets, and thus efficient strategies for processing and
Fig. 9 Lateral ventricle region of mouse brain (coronal section).
a MS image, 3 lm pixel size, 170 9 300 pixels, green phosphati-
dylcholine PC (38:4), [M ? K]?, m/z 848.5566. blue phosphatidyl-
choline PC (34:1), [M ? K]?, m/z 798.5410, red background signal
from ITO-coated glass slide. b Optical image of imaged area before
measurement. c Mass spectrum acquired from a single 3-lm pixel
Fig. 10 MS images of phospholipids in tissue sections at different
pixel size settings. a Mouse brain (coronal section), pixel size 5 lm,
170 9 170 pixels. b mouse brain (horizontal section), pixel size
50 lm, 207 9 260 pixels. c Intestinal tract of rat (part of whole body
section), pixel size 200 lm, 128 9 150 pixels
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analyzing are essential. A common data format for the
flexible exchange and processing of mass spectrometry
imaging data was developed within the EU joint project
COMPUTIS (www.computis.org). The data format is in
part based on the HUPO-PSI format mzML (Martens et al.
2011) and was thus called imzML for ‘imaging mzML.’
The concept of imzML and application examples are
summarized in Schramm et al. (2012). Additional infor-
mation and all technical details necessary to implement
imzML are provided in a book chapter (Ro¨mpp et al.
2010c) and on the Web site www.imzml.org.
MS imaging data in imzML format are divided into two
separate files. Metadata (e.g. instrumental parameters and
sample details) are stored in an XML file. Information in this
file is organized in a controlled vocabulary in order to avoid
ambiguities (Smith et al. 2007). Mass spectra are stored in a
separate binary file in order to ensure efficient data storage.
The XML structure in combination with the controlled
vocabulary ensures that the data format can be easily
adapted to new instrumentation and experimental strategies.
Data sets from more than 10 different MS imaging plat-
forms have been converted into imzML so far. Examples
shown in Fig. 11 include data from matrix-assisted laser
desorption/ionization (MALDI) as well as desorption elec-
trospray ionization (DESI) and secondary ion mass
spectrometry (SIMS). A growing number of processing
options are available for the imzML format. The lower part
of Fig. 11 shows software tools which were developed by
COMPUTIS partners. imzML can also be employed for
processing data with different tools sequentially as demon-
strated in Schramm et al. (2012). Additional examples of
imzML conversion and processing options are displayed in
the ‘imzML gallery’ on www.imzml.org. imzML-based
software was also used to process data from our high-reso-
lution mass spectrometry imaging method. While the small
pixel size is not a problem, some software tools need to be
adapted to handle high mass resolution data (i.e. to generate
MS images with a narrow bin width of Dm/z = 0.01).
imzML can also be used to compare data from different
instrument platforms. Options for data processing (e.g.
binning, normalization) and visualization (e.g. interpola-
tion options, color schemes) vary strongly between differ-
ent MS imaging software tools and can make a direct
comparison of data difficult. This problem can be avoided
if all data sets are converted to imzML and the data are
displayed with identical parameters of one software tool
[see Schramm et al. (2012) for details].
The concept of imzML is also actively supported by
major vendors of MS imaging instrumentation including
Thermo Fisher Scientific (Bremen, Germany), Waters
Fig. 11 Combination of data from different MS imaging platforms and software tools on the basis of the common data format imzML. See
Schramm et al. (2012) for details
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Corporation (Manchester, UK) and Bruker Daltonik (Bre-
men, Germany). An updated list of available tools and
workflows can be found on the imzML Web site. This also
includes the first commercial software tools, which are
compatible with imzML, from Imabiotech (2012) and
PREMIERBiosoft (2012).
imzML provides more flexibility in data processing as
the user is no more limited to proprietary software but can
choose the processing option that best fits the purpose. Data
can also easily be shared between collaborators as several
of the software tools are freely available. Measurement
results can be provided to partners in biological or clinical
laboratories without the loss of information (which is the
case when sharing only the images). Finally, a common
data format provides more transparency in reporting MS
imaging results. Consequently, imzML can facilitate
everyday work with MS imaging data.
Conclusion and perspective
The results presented above demonstrate that mass spec-
trometry imaging with high molecular specificity is possi-
ble at or close to cellular dimensions. Lipids,
(neuro)peptides and drug compounds were imaged in a
wide range of biological samples at a spatial resolution of
5–10 lm. A measurement of mouse urinary bladder at
5 lm step size showed pixel-sharp separation between
tissue regions. A drug compound (imatinib) was imaged in
mouse kidney at 10 lm pixel size. Correlation with spatial
distributions of (simultaneously detected) phospholipids
allowed to directly link areas of imatinib accumulation to
histological structures. More than 10 neuropeptides were
imaged at 5 and 10 lm pixel size in mouse pituitary gland.
Peptide identification by accurate mass was confirmed by
additional MS/MS imaging experiments.
On-tissue digestion was employed for the analysis of
proteins. Tryptic peptides were imaged for the first time with
accurate mass and identified by complementary LC–ESI–MS/
MS measurements of an adjacent tissue section. This
approach significantly increased both the reliability and the
number of peptide identifications. In subsequent experiments,
the spatial resolution for tryptic peptides was improved to
50 lm while maintaining the high molecular specificity. This
was achieved by applying trypsin with a spraying device.
A dedicated sample preparation protocol was estab-
lished for the analysis of cell cultures. Phospholipids and
smaller metabolites such as amino acids and nucleic acids
were imaged in single cells. A full metabolic profile was
obtained from a single pixel of 7 9 7 lm2.
The feasibility of obtaining high-quality mass spec-
trometry imaging data from clinically relevant tissue was
demonstrated by the analysis of lung carcinoma tissue. The
highest spatial resolution of a MALDI imaging experiment
of tissue so far was obtained by analyzing a mouse brain
section at 3 lm pixel size.
MS image analysis for all these experiments showed
excellent correlation with histological evaluation. In addi-
tion, it provided highly specific molecular information. In
many cases, components of very similar mass (Dm/z \ 0.1)
showed distinctly different spatial distributions. This
demonstrated the need for accurate mass determination in
order to obtain reliable information from MS imaging
experiments of biological samples. The ability to combine
high mass resolution and accuracy with a high spatial
resolution in the low micrometer range is a unique feature
of the presented method.
Each of these studies represented a significant improve-
ment in spatial resolution and/or reliability of identification
compared to studies reported earlier. These methodological
improvements were made possible by the development of an
integrated workflow that is optimized for ‘mass spectrome-
try imaging with high resolution in mass and space.’ The
experiments presented above were not merely the applica-
tion of one method to different samples, but involved new
experimental approaches for each study. For example,
sample preparation was carefully adjusted for each appli-
cation. This was especially important for the analysis of
single cells and the detection of tryptic peptides, but also for
the analysis of highly water-soluble analytes such as neu-
ropeptides and drug compounds.
While small pixel size is not necessarily a prerequisite
for high-quality MS imaging, higher mass accuracy and
mass resolution will always result in more reliable data.
The high complexity of biological samples inevitably leads
to multiple peaks for each nominal mass. High mass
accuracy significantly improves the reliability of identifi-
cation as demonstrated in the examples above. This is even
more important when different MS methods are combined
as shown for the example of tryptic peptides. Therefore,
MS imaging experiments should always be designed as to
deliver the highest mass accuracy and mass resolution
possible (for a given instrumental setup). More frequent
mass calibration steps, internal standards and/or postrun
recalibration can be used to achieve this goal.
Up to now, we have applied our mass spectrometry
imaging method to a wide variety of applications. Targeted
compound classes included lipids, amino acids, peptides,
proteins, nucleic acids, carboxylic acids and carbohydrates.
In addition to the examples discussed above, we have
analyzed several sample types including muscle, testis,
spinal disk as well as adrenal gland tissue originating from
mouse, rat, pig or cow. In these experiments ‘mass spec-
trometry imaging with high resolution in mass and space’
proved to be a versatile and robust method for the highly
detailed analysis of biological samples.
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A major focus of our current and future studies is the
analysis of clinical tissue samples. Several types of human
tumor biopsies are currently being analyzed. Sets of care-
fully selected samples will be analyzed in close collabo-
ration with clinical partners. On the methodological side,
the current activities are aimed at further improving mea-
surement speed, sensitivity and spatial resolution. In
addition to optimizing existing protocols, new application
areas are being explored. This includes the analysis of
material from plants, insects and fungi.
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